David A. Siegel Jazz Pharmaceuticals PLC Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Jazz Pharmaceuticals PLC stock. As of the latest transaction made, Two Sigma Advisers, LP holds 81,700 shares of JAZZ stock, worth $11.3 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

81,700

Previous 106,000 22.92%

Holding current value

$11.3 Million

Previous $11.8 Million 14.84%

% of portfolio

0.02%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$107.32 - $127.74 $2.61 Million - $3.1 Million	-24,300 Reduced 22.92%	81,700 $10.1 Million
Q3 2024 Nov 14, 2024	BUY	$100.57 - $116.37 $8.5 Million - $9.83 Million	84,500 Added 393.02%	106,000 $11.8 Million
Q2 2024 Aug 14, 2024	SELL	$103.94 - $118.98 $20,788 - $23,796	-200 Reduced 0.92%	21,500 $2.29 Million
Q1 2024 May 15, 2024	BUY	$115.19 - $132.77 $1.87 Million - $2.15 Million	16,200 Added 294.55%	21,700 $2.61 Million
Q4 2023 Feb 14, 2024	SELL	$114.26 - $136.0 $4.67 Million - $5.56 Million	-40,900 Reduced 88.15%	5,500 $676,000
Q3 2023 Nov 14, 2023	SELL	$122.0 - $145.31 $12 Million - $14.3 Million	-98,400 Reduced 67.96%	46,400 $6.01 Million
Q2 2023 Aug 14, 2023	SELL	$122.5 - $147.16 $5.75 Million - $6.9 Million	-46,900 Reduced 24.47%	144,800 $18 Million
Q1 2023 May 15, 2023	SELL	$133.98 - $160.47 $2.34 Million - $2.81 Million	-17,500 Reduced 8.37%	191,700 $28.1 Million
Q4 2022 Feb 14, 2023	BUY	$129.72 - $159.85 $12.2 Million - $15.1 Million	94,400 Added 82.23%	209,200 $33.3 Million
Q3 2022 Nov 14, 2022	BUY	$126.59 - $161.18 $8.34 Million - $10.6 Million	65,900 Added 134.76%	114,800 $15.3 Million
Q2 2022 Aug 15, 2022	BUY	$141.59 - $168.66 $4.63 Million - $5.52 Million	32,700 Added 201.85%	48,900 $7.63 Million
Q1 2022 May 16, 2022	BUY	$129.64 - $160.7 $1.28 Million - $1.59 Million	9,900 Added 157.14%	16,200 $2.52 Million
Q4 2021 Feb 14, 2022	BUY	$119.87 - $145.67 $755,181 - $917,720	6,300 New	6,300 $803,000
Q3 2021 Nov 15, 2021	SELL	$128.64 - $184.79 $308,735 - $443,496	-2,400 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$160.2 - $186.42 $1.28 Million - $1.49 Million	-7,985 Reduced 76.89%	2,400 $426,000
Q1 2021 May 17, 2021	BUY	$150.19 - $173.5 $1.56 Million - $1.8 Million	10,385 New	10,385 $1.71 Million
Q3 2020 Nov 16, 2020	SELL	$105.46 - $144.13 $3.83 Million - $5.23 Million	-36,285 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$95.68 - $121.88 $1.11 Million - $1.41 Million	11,585 Added 46.9%	36,285 $4 Million
Q1 2020 May 15, 2020	SELL	$87.74 - $152.74 $6.1 Million - $10.6 Million	-69,485 Reduced 73.78%	24,700 $2.46 Million
Q4 2019 Feb 14, 2020	BUY	$117.65 - $153.73 $6.98 Million - $9.13 Million	59,360 Added 170.45%	94,185 $14.1 Million
Q3 2019 Nov 14, 2019	SELL	$125.18 - $143.24 $45.2 Million - $51.8 Million	-361,285 Reduced 91.21%	34,825 $4.46 Million
Q2 2019 Aug 14, 2019	SELL	$125.55 - $144.48 $17 Million - $19.6 Million	-135,800 Reduced 25.53%	396,110 $56.5 Million
Q1 2019 May 15, 2019	BUY	$121.81 - $142.95 $39.7 Million - $46.6 Million	326,300 Added 158.7%	531,910 $76 Million
Q4 2018 Feb 14, 2019	BUY	$115.94 - $166.74 $794,536 - $1.14 Million	6,853 Added 3.45%	205,610 $25.5 Million
Q3 2018 Nov 14, 2018	SELL	$161.01 - $180.57 $6.07 Million - $6.81 Million	-37,700 Reduced 15.94%	198,757 $33.4 Million
Q2 2018 Aug 14, 2018	BUY	$146.33 - $183.18 $21.3 Million - $26.6 Million	145,300 Added 159.4%	236,457 $40.7 Million
Q1 2018 May 15, 2018	BUY	$135.59 - $157.16 $899,910 - $1.04 Million	6,637 Added 7.85%	91,157 $13.8 Million
Q4 2017 Feb 14, 2018	BUY	$131.06 - $150.39 $11.1 Million - $12.7 Million	84,520	84,520 $11.4 Million

Others Institutions Holding JAZZ

# of Institutions

543

Shares Held

59M

Call Options Held

125K

Put Options Held

58.4K

View Full List

About Jazz Pharmaceuticals plc

Ticker JAZZ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,680,700
Market Cap $8.7B
Description
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement ...

More about JAZZ

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account